Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with early-stage endometrial (uterine) cancer (stages 1 or 2 under the FIGO 2023 classification system) where scans such as CT, MRI, or PET/CT show the cancer appears to be confined to the uterus.
- People who do not have any other active cancer at the same time as their endometrial cancer diagnosis.
- People who have not received any cancer treatment (such as chemotherapy or radiation) before surgery.
- People who are willing and able to give written informed consent to participate in the study.
Who may not be able to join:
- People who have a medical reason why methylene blue dye (used during the surgical procedure) cannot be safely used, or who cannot safely undergo the specific type of keyhole surgery used in this trial (confirm with trial site).
- People who have previously had surgery for a cancer diagnosis.
- People with severe or deeply embedded endometriosis (a condition where uterine-like tissue grows outside the uterus), or whose uterus is significantly enlarged in a way that may make the surgical approach difficult.
- People who are currently receiving or have received pre-surgery cancer treatment (such as chemotherapy or radiation therapy).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Behzat Can, Assoc. Prof., Health Sciences University Gazi Yasargil Training and Research Hospital
Phone: +905536476838
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Total operation duration; Duration of right and left lymphadenectomy; Number of lymph nodes excised; number of positive lymph nodes; Hospitalization duration; Total bleeding volume; Difference between pre- and postoperative hemoglobin values; Surgical complications; Location o SLN; Preoperative and postoperative hematocrit values; Tumor's patological features; Management of complications; Duration of lateral colpotomy; Duration of hysterectomy; Sentinel lymphnode's side and number
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.